Previous studies demonstrated the trastuzumab displayed potent inhibition of multi-organ metastasis [27], and loss of HER2 facilitated distal metastasis of breast cancer patients receiving trastuzumab treatment [28], which indicating that trastuzumab resistance significantly associated with metastasis in breast cancer. The gene discussed is ERBB2; the disease is breast cancer.